As clinicians increasingly encounter patients with IBD as well as obesity, diabetes, or metabolic liver disease, there is a clear need to synthesize what is known about safety, metabolic effects, and IBD-specific outcomes to support evidence-informed clinical decision-making, explains senior investigator and study author Jolle St-Pierre, MD, PhD, FRCPC, a clinical assistant professor in the Division of Gastroenterology and Hepatology at the University of Calgary, Canada, in an email to Gastro Today
Any injectable product with unclear licensing, unclear ingredients, or unreliable sourcing raises safety questions
Lancet 381 , 19051915 (2013)
Acknowledgments The authors would like to thank SHRM, and particularly SHRM Tennessee and SHRM Austin, as well as the Midwest Business Group on Health, the NC Business Coalition on Health, and The Alliance for their assistance in organizing the focus groups